Muscuron 4 mg/vial Injection
PDF Leaflet Revision Date: 03 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to general anaesthesia for intubation and muscle relaxation.
Dosage (summary)
Intubating dose: 0.08-0.10 mg/kg IV; Maintenance: 0.03-0.05 mg/kg.
Onset of Action / Duration
Onset: 90-120 secs, Duration: 24-60 mins.
Special Populations
- Hepatic impairment
- Renal failure
- Severe obesity
- Neuromuscular disease
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Anaesthetics (e.g., isoflurane, halothane)
- Aminoglycosides
- Corticosteroids
- Magnesium salts
Contraindications
- Hypersensitivity to vecuronium or excipients
- Children under 3 months
- Pregnancy and lactation
Common side effects
- Hypersensitivity reactions
- Flaccid paralysis
- Respiratory insufficiency
- Hypotension
Counselling Points
- Monitor respiratory function during recovery.
- Avoid use in patients with known hypersensitivity.
- Ventilatory support mandatory until recovery.
Serious warnings
- Respiratory paralysis possible
- Anaphylactic reactions may occur
- Residual neuromuscular blockade
Important Disclaimer
The Muscuron 4 mg/vial Injection professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
